Report of Foreign Issuer (6-k)
August 29 2018 - 8:01AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
W
ashington,
D.C.
20549
FORM
6-K
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16
of the
Securities Exchange Act of 1934
For
the month of August 2018
Commission
File Number: 001-37643
KITOV
PHARMA
LTD.
(Translation
of registrant's name into English)
One
Azrieli Center, Round Tower,
Tel
Aviv 6701101, Israel
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form
20-F ☒ Form 40-F ☐
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____
On
August 29, 2018, Kitov Pharma
Ltd. (the “Company” or the “Registrant”) issued a Press Release:
“
Kitov Pharma Provides Corporate Update and Reports First Half 2018 Financial Results.
” A copy of this press
release, together with the Company’s unaudited condensed consolidated interim financial statements as of June 30, 2018,
and for the six months then ended, are furnished herewith as Exhibits 99.1 and 99.2, respectively.
The information contained within this report
on Form 6-K and all Exhibits attached hereto should be read in conjunction with (1) our Unaudited Condensed Consolidated Interim
Financial Statements as of June 30, 2018, and for the six months then ended; and, (2) our audited consolidated financial statements
for the year ended December 31, 2017, which appears in the Company’s Annual Report on Form 20-F filed with the Securities
and Exchange Commission on March 5, 2018, as well as the other information contained in such Annual Report on Form 20-F and in
our Registration Statements and Prospectuses filed with the SEC.
The
text which is found under the headings entitled “Financial Results for Six Months Ended June 30, 2018” and “Balance
Sheet Highlights”, respectively, in Exhibit 99.1 attached hereto; and, the entire Exhibit 99.2 attached hereto, are all
hereby incorporated by reference into each of the Registrant’s Registration Statements on Form F-3 filed with the Securities
and Exchange Commission on December 12, 2016 (Registration file numbers 333-207117, 333-211477 and 333-215037), the Registrant’s
Registration Statement on Form S-8 filed with the Securities and Exchange Commission on May 20, 2016 (Registration file number 333-211478),
the Registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission on June 6, 2017 (Registration
file number 333-218538), and the Registrant’s Registration Statement on Form F-3 filed with the Securities and Exchange
Commission on July 16, 2018 (Registration file number 333-226195).
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorized.
|
KITOV
PHARMA LTD.
|
|
|
August
29, 2018
|
By:
|
/s/
Simcha Rock
|
|
|
Simcha
Rock
|
|
|
CFO
and Director
|
Kitov Pharma (NASDAQ:KTOV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Kitov Pharma (NASDAQ:KTOV)
Historical Stock Chart
From Apr 2023 to Apr 2024